← FDA DRUG APPROVALS
FDA ANDA · ANDA212141
SUCRALFATE ORAL SUSPENSION
sucralfate
Sponsor: GLENMARK PHARMS LTD
APPLICATION
ANDA212141
TYPE
ANDA
ORIGINAL APPROVAL
2026-01-05
LATEST ACTION
2026-01-05
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription
Products
SUCRALFATEPrescription
SUCRALFATE 1GM/10ML · SUSPENSION · ORAL
Approval history
2026-01-05UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.